TRAK2

Across TCGA pan-cancer cohorts, TRAK2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAK2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRAK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where TRAK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.599	1.000	.013	26	view →
LUAD	OS	Median	II,III,IV	0.798	0.415	.017	6	view →
PDAC	DFS	Median	III,IV	0.818	0.417	.040	2	view →
GBM	OS	Median	All	0.965	0.741	.048	1	view →
LSCC	OS	Quartile	II,III,IV	0.883	0.556	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAK2–CCRCC (DFS)

Open the CCRCC breakdown →